MARKET

NVIV

NVIV

InVivo
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.630
+0.060
+3.82%
Opening 10:44 08/12 EDT
OPEN
1.570
PREV CLOSE
1.570
HIGH
1.660
LOW
1.570
VOLUME
146.59K
TURNOVER
--
52 WEEK HIGH
22.50
52 WEEK LOW
1.085
MARKET CAP
7.96M
P/E (TTM)
-0.0553
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NVIV stock price target is 37.50 with a high estimate of 37.50 and a low estimate of 37.50.

EPS

NVIV News

More
CLDX, AMC among premarket gainers
Seeking Alpha - Article · 06/10 13:15
33 Stocks Moving in Tuesday's Pre-Market Session
Gainers
Benzinga · 06/02 11:04
TRNX, ATOS, RAD and ATHX among midday movers
Seeking Alpha - Article · 04/16 16:39
InVivo Therapeutics launches $3M direct offering; shares down 8% premarket
seekingalpha · 04/16 15:14
GT, RAD among premarket losers
Seeking Alpha - Article · 04/16 13:09
InVivo Therapeutics Announces $3.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
Business Wire · 04/16 00:30
AR, CORR, SPCE and NBEV among midday movers
Seeking Alpha - Article · 04/14 16:40
NVAX, INSG among premarket gainers
Seeking Alpha - Article · 04/01 13:20

Industry

Advanced Medical Equipment & Technology
+1.59%
Healthcare Equipment & Supplies
+1.52%

Hot Stocks

Symbol
Price
%Change

About NVIV

InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company's approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. The Neuro-Spinal Scaffold consists of biocompatible and bioresorbable polymers, which include poly lactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL). The Company is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.
More

Webull offers kinds of Invivo Therapeutics Holdings Corp stock information, including NASDAQ:NVIV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVIV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVIV stock methods without spending real money on the virtual paper trading platform.